Profese online 2020, 13(1):46-55 | DOI: 10.5507/pol.2020.010

Patient life style with anti-coagulation treatment: first results of the pilot study

Anna Zatloukalová1,2,3, Miroslav Homza4, Martina Kovalová1
1 Ústav epidemiologie a ochrany veřejného zdraví, Lékařská fakulta, Ostravská univerzita, Ostrava, Česká republika
2 Ústav zdravotnického managementu, Fakulta zdravotnických věd, Univerzita Palackého v Olomouci, Olomouc, Česká republika
3 Centrum vědy a výzkumu, Fakulta zdravotnických věd, Univerzita Palackého v Olomouci, Olomouc, Česká republika
4 Katedra interních oborů, Lékařská fakulta, Ostravská univerzita, Ostrava, Česká republika

Background: Lifestyle is an important risk factor for many, especially non-infectious diseases such as cardiovascular diseases. These are diseases with a long-term high incidence and mortality in the Czech Republic and abroad. They are often very preventable. Anticoagulants reduce pathologically increased blood coagulation in many of these diseases. In addition to the most commonly used Warfarin, we now have new direct oral anticoagulants (Pradaxa, Xarelto, Eliquis, Lixiana).

Objective: The aim of the pilot study is to obtain valuable information about the lifestyle of patients receiving anticoagulant treatment.

Methods: The information was collected through a questionnaire survey. The questionnaire was compiled on the basis of standardised questions used in large population epidemiological studies.

Results: The average body mass index (BMI) was in the obesity zone. Men were more in the area of overweight, women in the obesity zone. The most common comorbidity was hypertension and diabetes mellitus II. Type. More than half of them were not comprehensively educated in the area of healthy lifestyle, a quarter were not educated at all. According to the CHA2DS2-VASc score, patients were at high risk of thromboembolism (score ≥ 2).

Conclusions: Lifestyle remains one of the most important and often very preventable factors that act not only as a risk but also as a prevention of many cardiovascular diseases, including those requiring anticoagulant therapy.

Keywords: risk factors, prevention, cardiovaskular diseases, livestyle

Received: April 2020; Accepted: June 2020; Published: July 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zatloukalová, A., Homza, M., & Kovalová, M. (2020). Patient life style with anti-coagulation treatment: first results of the pilot study. Profese Online, 13(1), 46-55. doi: 10.5507/pol.2020.010
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kábrt J. Životní styl a riziko civilizačních nemocí. Vnitř lék. 2014;60(5-6):458-461. Go to PubMed...
    2. Hamplová L. Veřejné zdravotnictví a výchova ke zdraví: pro zdravotnické obory. Praha: Grada Publishing; 2019.
    3. Cífková R, Vaverková H, Filipovský J, Aschermann M. Summary of the European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): Prepared by the Czech Society of Cardiology. Cor et Vasa [Internet]. 2014 [cited 2020 Jan 5];56(2):[e169-e189]. Available from: http://e-coretvasa.cz/doi/10.1016/j.crvasa.2014.02.009.html Go to original source...
    4. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease. CHEST Guideline and Expert Panel Report. CHEST. 2016;149(2):315-352. Go to original source... Go to PubMed...
    5. Barnes GD, Ageno W, Ansell J, Kaatz S. For the subcommittee on the control of anticoagulation. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(6):1154-1156. Go to original source... Go to PubMed...
    6. Penka M, Matýšková M, Michalcová J. Ohlédnutí za vývojem antitrombotické profylaxe s akcentem na posledních 25 let. Transfuze Hematol dnes. 2019;25(1):56-64.
    7. Pohlídalová A, Janoutová J, Homza M, Janout V. Nová antikoagulancia. Prakt Lék. 2016;96(3):114-121.
    8. Jones WS, Hellkamp AS, Halperin J, Piccini JP, Breithardt G, Singer DE, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J [Internet]. 2014 [cited 2020 Apr 1];35(4):[242-249 p.]. Available from: https://academic.oup.com/eurheartj/article/35/4/242/466987. Go to original source... Go to PubMed...
    9. Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol [Internet]. 2013 May [cited 2020 Apr 1];61(19):[1998-2006 p.]. Available from: https://pubmed.ncbi.nlm.nih.gov/23500298/ Go to original source... Go to PubMed...
    10. Granger CHB, Alexander JH, Mcmurray JV, et al. for the aristotle committees and investigators. Apixaban versus warfarin in patients with atrial fi brillation. Engl J Med [Internet]. 2011 Sep [cited 2020 Apr 1];365(11):[981-982 p.]. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa1107039 Go to original source... Go to PubMed...
    11. Kuan HNg, et al. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age And Ageing [Internet]. 2016 Jan [cited 2020 Apr 1];45(1):[77-83 p.]. Available from: https://academic.oup.com/ageing/article/45/1/77/2195286 Go to original source... Go to PubMed...
    12. Kvasnička J, Penka M, Kvasnička T, et al. Doporučení české společnosti pro trombózu a hemostázu České lékařské společnosti J. E. Purkyně pro bezpečnou léčbu novými perorálními antikoagulancii (NOAC) - dabigatran exilátem, apixabanem a rivaroxabanem. Vnitř Lék. 2015;61(6):537-546. Go to PubMed...
    13. Zatloukalová A, Janoutová J, Homza M, Machaczka O, Janout V. Epidemiologická studie nových antikoagulancií. Klin Farmakol Farm. 2018;32(2):3-7. Go to original source...
    14. Špinar J, Vítovec J, Špinarová L, Musil L. Profile of Czech AF 2012. Profile of atrial fibrillation patients receiving antithrombotic therapy. Cor et Vasa [Internet]. 2014 [cited 2020 Apr 1];56(3):[e207-e216 p.]. Available from: https://www.sciencedirect.com/science/article/pii/S001086501400040X Go to original source...
    15. Žejglicová K, Kratěnová J, Lustigová M, Čapková N, Kubínová R. Vybrané ukazatele zdravotního stavu české populace - výsledky studie EHES 2014. Prakt lék [Internet]. 2017 [cited 2020 Apr 1];97(3):[123-130 p.]. Available from: http://www.prolekare.cz/prakticky-lekar-clanek/vybraneukazatele-zdravotniho-stavu-ceske-populace-vysledky-studie-ehes-2014-61210
    16. Čihák R, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Summary of the document prepared by the Czech Society of Cardiology. Cor et Vasa [Internet]. 2016 [cited 2020 Apr 1];58(6):[e636-683 p.]. Available from: http://www.sciencedirect.com/science/article/pii/S0010865016301047 Go to original source...
    17. Souhrn údajů o přípravku (ELIQUIS). The European medicines agency: Science medicines health. Available from: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR__Product_Information/human/002148/WC500107728.pdf
    18. Souhrn údajů o přípravku (LIXIANA). SÚKL: Státní ústav pro kontrolu léčiv. Available from: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR__Product_Information/human/002629/WC500189045.pdf.
    19. Souhrn údajů o přípravku (PRADAXA). The European medicines agency: Science medicines health. [online]. Available from: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR__Product_Information/human/000829/WC500041059.pdf
    20. Souhrn údajů o přípravku (XARELTO). The European medicines agency: Science medicines health. Available from: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR__Product_Information/human/000944/WC500057108.pdf
    21. Příbalová informace: Informace pro uživatele. Warfarin Orion 3 mg. Warfarin Orion 5 mg tablety warfarinum natricum. SÚKL: Státní úřad pro kontrolu léčiv. Available from: http://www.sukl.cz/modules/medication/detail.php?code=0094113&tab=texts
    22. Heinc P, Kováčik F, Moravec O, Přeček J, Táborský M. Nová doporučení pro léčbu fibrilace síní. Inter med pro prax [Internet]. 2013 [cited 2020 Apr 1];15(2):[52-58 p.]. Available from: https://www.internimedicina.cz/pdfs/int/2013/02/03.pdf
    23. Hutyra M, Šaňák D. Embolic ischemic strokes. Vnit Lek [Internet]. 2014 Dec [cited 2020 Apr 1];60(12):[1040-1049 p.]. Available from: http://www.vnitrnilekarstvi.eu/vnitrni-lekarstvi-clanek/embolizacni-ischemickecevni-mozkove-prihody-51220

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content